GlassScriptPhysician profile
Andrew J Ridder
NPI 1285993253
$96,905.58
in general payments reported to CMS, 2019-2025
33 companies · $234 in 2025
The $234 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $11K · 2021: $21K · 2022: $16K · 2023: $27K · 2024: $1,680 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Consulting Fee: $6,075 · Education: $1,422 · Food and Beverage: $1,290 · Travel and Lodging: $821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,575.00 |
| Consulting Fee | $6,075.00 |
| Education | $1,422.49 |
| Food and Beverage | $1,290.16 |
| Travel and Lodging | $820.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $88,069.29 | 2019-2024 | Ingrezza, Ongentys |
| Livanova USA, INC. | $2,519.93 | 2019 | |
| Medtronic USA, INC. | $1,612.47 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $1,380.84 | 2024-2025 | Ongentys 50mg Capsules 30, Ongentys, Crexont |
| Boston Scientific Corporation | $1,351.45 | 2019-2024 | Vercise |
| Medtronic, INC. | $677.41 | 2021 | |
| Abbvie INC. | $238.71 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $116.01 | 2019-2024 | Austedo |
| Genentech USA, INC. | $107.50 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Eisai INC. | $83.99 | 2019-2021 | |
| Abbott Laboratories | $78.91 | 2019-2025 | Infinity |
| Kyowa Kirin, INC. | $76.04 | 2020-2024 | Nourianz |
| Allergan, INC. | $57.47 | 2019-2020 | |
| Merz North America, INC. | $49.48 | 2019-2020 | |
| Lundbeck LLC | $46.98 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $43.80 | 2019 | |
| Sk Life Science, INC. | $43.36 | 2023-2024 | |
| Vanda Pharmaceuticals INC. | $35.05 | 2025 | Ponvory |
| Merz Pharmaceuticals, LLC | $33.01 | 2023-2025 | Xeomin, Inbrija, Ampyra |
| Celgene Corporation | $30.79 | 2023-2025 | Zeposia |
| Biohaven Pharmaceuticals, INC. | $30.64 | 2021 | |
| Portola Pharmaceuticals, LLC | $25.37 | 2019 | |
| Neurelis, INC. | $24.99 | 2023 | Valtoco |
| Catalyst Pharmaceuticals, INC. | $23.76 | 2023 | Fycompa |
| Grt US Holding, INC. | $23.25 | 2021 | |
| Genzyme Corporation | $20.86 | 2019 | |
| Axsome Therapeutics, INC. | $20.22 | 2025 | Symbravo |
| Mdd US Operations, LLC | $17.81 | 2023 | Gocovri |
| Pfizer INC. | $16.38 | 2023 | |
| Acadia Pharmaceuticals INC | $13.59 | 2019 | |
| Bio Products Laboratory USA, INC. | $12.90 | 2023 | Coagadex, Gammaplex |
| Emd Serono, INC. | $11.69 | 2021 | |
| Sunovion Pharmaceuticals INC. | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Ridder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.